基因编辑与基因组学专区
CRISPR 编辑公司 + AI 药物发现 —— 临床期、二元数据
基因编辑 + 计算/AI 药物发现 —— 多为临床期、尚未盈利的公司,价值取决于二元的试验数据,由一家盈利、已去风险的龙头压舱。层级为人工策展,价格为公开数据实时(延迟)行情。非投资建议。
CRISPR / 基因编辑公司
编辑平台 —— 一家已有获批疗法,其余处于临床期、成败取决于试验数据。VRTX 是已去风险、盈利的压舱锚(CRISPR 商业化伙伴)。
De-risked anchor: profitable mega-cap, commercial CRISPR partner (Casgevy) + dominant cystic-fibrosis franchise.
First approved CRISPR therapy (Casgevy, with VRTX) + pipeline; commercial-but-early.
In-vivo gene editing; positive Phase 3 (hereditary angioedema) — an in-vivo first.
Base-editing platform (more precise than cut-CRISPR); clinical-stage, pre-revenue.
Gene-editing; smallest and most troubled of the editors — very high risk, frequent strategy shifts.
AI 药物发现与精准医疗
用计算 / AI 设计分子、解读基因组与临床数据的平台。多数尚未盈利,靠合作里程碑驱动。
Physics-based computational drug-design software + an internal pipeline — dual software + biotech value.
Image-based AI drug-discovery platform (absorbed Exscientia in 2024); pre-profit.
AI precision-medicine / diagnostics platform (genomic + clinical data); high-growth.
Generative-AI antibody design; small-cap, pre-commercial, partnership-milestone-driven.
Motion-based / computational drug discovery; clinical-stage, binary on trial readouts.
层级为人工策展 · 价格为公开数据实时(延迟)行情 · 仅供参考 · 非投资建议